Phio Pharmaceuticals Corp.

PHIO | NASDAQ

Price Alert Chart Builder DCF Calculator

$1.01

-$0.02 (-1.94%)

At close: Sep 21, 2026, 4:00 PM ET

$1.02

+$0.01 (+0.99%)

Pre-market: Sep 22, 2026, 4:00 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-1.94%

(1D)

Rating

Updated: Aug 12, 2026

Fundamentals Weak

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $11.73M

1D Range

1 1.05

52W Range

0.81 4.19

Valuation (TTM)

PE -0.75

PB 0.93

EV/EBITDA 0.14

Valuation (NTM)

Forward PE N/A

Forward PEG 0.01

Price Target $14

Cash Flow

FCF Yield -138.2%

SBC Adj. FCF Yield -146.9%

SBC Impact -6.3%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y 0.1% | -49.4%

FCF 3Y | 5Y -33.1% | -4.6%

Returns

ROA -90.2%

ROE -87.4%

ROIC -100.5%

Financial Health

Net Cash

$13M

Current Ratio 15.87

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designe...

Sector Healthcare

Industry Biotechnology

Employees 6

IPO Date May 9, 2012

Website www.phiopharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$14

Upside

+1286.14%

Buy (1)

Hold (0)

Sell (0)

Analyst Details ➞